[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Michael Wang, MD

Myeloma Specialist

Specialities: Multiple Myeloma

Spoken languages: English

Clinical Expertise

  • Multiple Myeloma

About

I am a Professor in the department of Lymphoma & Myeloma at MD Anderson. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I completed my clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.

I have published more than 150 peer-reviewed papers and have presented my work at meetings nationally and internationally. I am the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.

During the past 15 years, I have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. My clinical research of the Bruton’s tyrosine kinase inhibitor ibrutinib was published in the New Eng. J. Med. in 2013. I am currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL. I am also the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.

Location

MD Anderson Cancer Center: 1515 Holcombe Blvd, Houston, TX 77030, USA

newsletter icon

Get the latest thought leadership on your Blood Cancer delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.